XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Clinical trial NCT06902376 · RECRUITING

Trial details

NCT number: NCT06902376
Sponsor: UNC Lineberger Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Anaplastic Thyroid Cancer Thyroid Cancer BRAF Mutation-Related Tumors

Start date: 2025-06-03
Primary completion: 2028-03-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.